

Dear Colleagues,

Following the series of TOPICAL GLP-1 training sessions BSol CCG organised for clinicians prior to the Covid19 pandemic, BSol Training Hub in collaboration with Lilly have organised a series of sessions on the **Practicalities of starting GLP-1 therapy** [during this Covid19 pandemic].

Please note this education is aimed at clinicians who:

1. Have attended the GLP-1 day from Topical 2 and need a refresher/increase confidence
2. Will be initiating and managing GLP-1 medications in practice.

The objectives of the session include:

- To understand how the physiological benefits of native GLP-1 have been translated into the therapeutic class of GLP-1 RAs
- To examine existing guidelines and their application to practice
- To explore the impact of cardiovascular data on evolving guidance
- To explore differences between the most commonly prescribed GLP-1 Receptor Agonists
- To use case studies to illustrate key points

This should help to identify the appropriate patient for optimisation to GLP1 injectable therapy and to develop the confidence in injectable initiation and care planning virtually.

It will help focus on the salient points for safe injectable initiation within the boundaries of social distancing.

As a part of this education process you will be asked to give feedback after a 3-month period on the number of GLP-1 initiations you have undertaken and challenges and opportunities the covid19 pandemic has presented you.

There will be a series of dates for each meeting aiming to provide flexibility and access. The meetings are aimed to be interactive with an opportunity to ask questions about patients relevant to the topic.

Yours faithfully,

Dr Atif Hassan
BSol CCG Clinical Lead in Diabetes Education
BSol CCG Clinical Lead in Diabetes for the South Birmingham Locality

and

Dr Imran Yakub
BSol CCG Clinical Lead in Diabetes for the East Birmingham Locality

Please see next page for webinar dates and booking information

Practicalities of starting a GLP-1 RA therapy

Training objectives:

- To understand how the physiological benefits of native GLP-1 have been translated into the therapeutic class of GLP-1 RAs
- To examine existing guidelines and their application to practice
- To explore the impact of cardiovascular data on evolving guidance
- To explore differences between the most commonly prescribed GLP-1 Receptor Agonists
- To use case studies to illustrate key points

Date	Time	Eventbrite link- select date on booking page
Tuesday 3 rd November	19.00-20.00	https://www.eventbrite.co.uk/e/125072909439
Saturday 7 th November	10.00-11.00	
Thursday 19 th November	13.00-14.00	
Thursday 26 th November	19.00-20.00	